ALNY
Alnylam Pharmaceuticals, Inc.
A biopharmaceutical company that makes RNAi therapeutics — medicines that "silence" disease-causing genes — with six marketed drugs including ONPATTRO, AMVUTTRA, GIVLAARI, and OXLUMO for rare conditions like ATTR amyloidosis. Founded in 2002 by Nobel laureate Phillip Sharp and fellow scientists, its name comes from Alnilam, the bright center star of Orion's belt, chosen as an "aspirational North Star" for genomic medicine. Its ONPATTRO was the first RNAi drug ever approved by the FDA, in 2018.
CUSIP: 02043Q107HealthcareUS2 holders
Total Value
$618.61M
Total Shares
2.05M
Net Share Change
+19.1K
Activity
1 buying1 selling
Investor
Value
Shares
Weight
Change
